Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.
about
Epigenetic screen of human DNA repair genes identifies aberrant promoter methylation of NEIL1 in head and neck squamous cell carcinomamiR-181d: a predictive glioblastoma biomarker that downregulates MGMT expressionIdentification of a CpG island methylator phenotype that defines a distinct subgroup of gliomaMiRNA expression patterns predict survival in glioblastomaGlioma Stem Cells: Signaling, Microenvironment, and TherapyTherapeutic approach beyond conventional temozolomide for newly diagnosed glioblastoma: Review of the present evidence and future directionEpigenetic mechanisms involved in melanoma pathogenesis and chemoresistanceThe three-layer concentric model of glioblastoma: cancer stem cells, microenvironmental regulation, and therapeutic implicationsO(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problemsMalignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methodsLong-term temozolomide might be an optimal choice for patient with multifocal glioblastoma, especially with deep-seated structure involvement: a case report and literature reviewFasting enhances the response of glioma to chemo- and radiotherapyMiR-221/222 target the DNA methyltransferase MGMT in glioma cellsNETRIN-4 protects glioblastoma cells FROM temozolomide induced senescenceEnhanced anti-tumor effect of zoledronic acid combined with temozolomide against human malignant glioma cell expressing O6-methylguanine DNA methyltransferaseCharacterization of a novel anti-cancer compound for astrocytomasA New Epigenetic Mechanism of Temozolomide Action in Glioma CellsTemozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 ExpressionPrognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastomaThe global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for gliomaSurvival in glioblastoma: a review on the impact of treatment modalities.Postradiation imaging changes in the CNS: how can we differentiate between treatment effect and disease progression?Improving the radiosensitivity of radioresistant and hypoxic glioblastoma.JLK1486, a Bis 8-Hydroxyquinoline-Substituted Benzylamine, Displays Cytostatic Effects in Experimental Gliomas through MyT1 and STAT1 Activation and, to a Lesser Extent, PPARγ ActivationCorrelation of apparent diffusion coefficient values measured by diffusion MRI and MGMT promoter methylation semiquantitatively analyzed with MS-MLPA in patients with glioblastoma multiforme.Restoration of sensitivity in chemo-resistant glioma cells by cold atmospheric plasma.Role of Nitric Oxide in Glioblastoma Therapy: Another Step to Resolve the Terrible Puzzle ?Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase.Temozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment.Craniospinal irradiation with concomitant and adjuvant temozolomide--a feasibility assessment of toxicity in patients with glioblastoma with a PNET component.Genetic signature of adult gliomas and correlation with MRI features.A comparison of long-term survivors and short-term survivors with glioblastoma, subventricular zone involvement: a predictive factor for survival?The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide.Bioenergetic metabolites regulate base excision repair-dependent cell death in response to DNA damage.Demethylating Agents in the Treatment of CancerNovel drugs in pediatric gliomas.Initial care and outcome of glioblastoma multiforme patients in 2 diverse health care scenarios in Brazil: does public versus private health care matter?.Pineal Region Glioblastoma, a Case Report and Literature Review.Comparative Study of Adjuvant Temozolomide Six Cycles Versus Extended 12 Cycles in Newly Diagnosed Glioblastoma Multiforme
P2860
Q21558627-7B0CB916-8843-4E79-8A6E-EC38EEBFC5A6Q24610377-6DAB610C-EDAD-43CA-85E3-C43FF89B4288Q24612429-7229DD9D-125C-4D2B-A4BB-45445683EA5FQ24629525-080323FB-938C-4E85-A31C-F9A4005D2594Q26765854-8F868EC6-3BE0-4245-AE57-E95300FE10DAQ26774717-BD683CE3-CE41-4696-A4D5-09B6D0C6EB64Q26778761-0C485400-4894-49AC-ADD9-9787898A3D75Q26829663-111D06C4-6E64-4F25-A970-A4E17313593AQ26853112-FE70BE25-0859-4595-9FCA-3E6BFDFF0CB3Q26853516-4084A02E-1F35-4E69-887E-F1B072CF2662Q27026704-165C07DB-B559-404E-8A36-FB86DEF5C5E9Q27320014-400CAD00-B0B6-497B-8196-A4F08A8047D2Q28118866-97284692-988F-4332-94D3-7B35D0E0A7A5Q28535039-B1D568FC-FA1D-4311-BA5C-FD2F8D2AB18BQ28541765-101F344B-0376-4B0F-89FC-764650C37E92Q28543237-D399EA8E-7B16-4B90-A55D-A475AD6CDAD1Q28547489-22D54F69-4BFE-4E3E-8518-8003768B245DQ28550138-12CDD5C2-DEEE-4EA2-AE88-C54800075617Q28731328-7C4C1984-B7D9-42E9-A055-6C54C4261EF8Q28741768-6D1E1F08-55DD-430E-B4CF-D62D04477C41Q30251810-723AE35E-7485-49BD-A3ED-C1C4AC72E2B8Q30418915-F63EF42A-508B-4876-9963-A143F54EF393Q30452219-C0AAA9FD-ABA1-4D4C-A60E-45A3611F3920Q30500762-65825B41-8ACE-4B1F-830D-29BEF0910929Q30571373-3E3456C6-B77B-4195-A6CC-9D9E9D4366F6Q31118089-3CBE1B17-DD0F-4BBF-93DA-1DA3F15F0B56Q33361853-8CEC6995-2627-476D-B29B-181944C07B6EQ33384898-DC1E9CEF-3437-4A29-B9EC-353C96B560C4Q33417537-CC1233D4-20BB-4DB5-9F89-27AEF39A96CBQ33427688-9284C79E-1C5B-435F-A798-3508FAA5A1C0Q33429765-F70CB6DA-FCCF-4A74-88D0-E92D26F9BCCBQ33509600-AA478DA1-BA19-4729-82CD-113C7E280D21Q33573296-AEDB8607-9142-4C2D-AE8B-95EF7D465D5EQ33578787-78418871-2E1F-453A-A308-0E3F2A30D4A9Q33598840-D2756D75-9124-430C-9C61-EAC90AAC1D29Q33678040-8D3CBCBA-3B32-4776-97BF-F24D76EAA646Q33685551-0723D050-CA24-41B4-A184-10A501FAB5D8Q33753453-B802F14B-643B-49E6-BB85-0A67CD964467Q33785684-53B97FF6-728A-45DF-AA3B-A287E0D13EF9Q33832441-1A36C866-6AA3-4614-89BC-342C0E38B03F
P2860
Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Correlation of O6-methylguanin ...... ies to modulate MGMT activity.
@en
Correlation of O6-methylguanine methyltransferase
@nl
type
label
Correlation of O6-methylguanin ...... ies to modulate MGMT activity.
@en
Correlation of O6-methylguanine methyltransferase
@nl
prefLabel
Correlation of O6-methylguanin ...... ies to modulate MGMT activity.
@en
Correlation of O6-methylguanine methyltransferase
@nl
P2093
P50
P356
P1476
Correlation of O6-methylguanin ...... ies to modulate MGMT activity.
@en
P2093
James G Herman
Mark R Gilbert
Minesh P Mehta
Roger Stupp
P304
P356
10.1200/JCO.2007.11.5964
P407
P577
2008-09-01T00:00:00Z